Accurately Identify IBS & IBD Earlier.
IsolateIBS-IBD™ offers providers an accurate new tool to identify Irritable Bowel Syndrome (IBS) or Inflammatory Bowel Disease (IBD) at the earliest onset of symptoms, and more importantly, to distinguish among IBS, Crohn’s and ulcerative colitis. The test uses a simple blood draw and delivers accuracy greater than 90%.
At IQuity, we understand the challenges of diagnosing IBS and IBD early and accurately. IBS is difficult to confirm by visual examination or measure with conventional diagnostic tools; typically diagnosis requires the provider to conduct a physical, take a detailed medical history, and monitor the presence of symptoms. A clinical process of elimination allows them to arrive at a diagnosis.
NOTE: Initially, the IsolateMS test will not be available in the following states: California, Florida, and New York. IQuity will update this list as licenses are obtained.
Research on IsolateIBS-IBD™
Using samples from diagnosed IBS/IBD patients as well as healthy subjects, IQuity applied machine learning to develop the proprietary algorithm that can accurately identify IBS vs IBD and within IBD, to distinguish between Crohn’s or ulcerative colitis.
IQuity studied more than 500 subjects, including patients with:
- inflammatory bowel disease: Crohn’s and ulcerative colitis
- irritable bowel syndrome
- disease controls: Celiac disease, colorectal cancer
- healthy patients
Standard calculations of sensitivity and specificity were employed to determine the accuracy of the results, which are greater than 90%.
Gastrointestinal conditions like IBS and IBD (Crohn’s and ulcerative colitis) can be challenging to diagnose because we rely primarily on a patient’s history and physical, along with other invasive procedures to make a determination. A test that will allow us to make a definitive call early is of value and can help make an accurate diagnosis because we can prescribe patients into an appropriate treatment regimen and diet sooner and minimize irreparable damage.